Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday

Vistagen Therapeutics (NASDAQ:VTGN) will likely be releasing its Q4 2025 earnings data before the market opens on Tuesday, June 10th. Analysts expect Vistagen Therapeutics to post earnings of ($0.53) per share and revenue of $0.18 million for the quarter.

Vistagen Therapeutics Stock Performance

Shares of NASDAQ VTGN opened at $2.42 on Tuesday. The company has a market capitalization of $69.85 million, a P/E ratio of -1.64 and a beta of 0.67. Vistagen Therapeutics has a 52-week low of $1.90 and a 52-week high of $4.21. The company’s 50 day moving average price is $2.30 and its 200-day moving average price is $2.60.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Vistagen Therapeutics stock. Cubist Systematic Strategies LLC acquired a new position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,088 shares of the company’s stock, valued at approximately $25,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.